Clinical trials: Respiratory Syncytial Viruses
Respiratory Syncytial Virus Infections
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
The purpose of this study is: To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately…
- Trial name
- RSV OA=ADJ=012 (NCT06534892)
- Testing
- RSVPreF3 OA vaccine
- Where
- 251 sites in United States, Australia and 15 more
- Volunteers
- 10,212 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
RSV Infection
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
This was a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who were at high risk for complications…
- Trial name
- RSVHR (NCT05568706)
- Testing
- EDP-938
- Where
- 84 sites in United States, Argentina and 10 more
- Volunteers
- 187 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Respiratory Syncytial Virus Infections
Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524
MEDI-524 given for up to 5 doses at 3 and 15 mg/kg to high-risk children appeared to be safe and well tolerated.
- Trial name
- NCT00192478
- Testing
- Medi-524
- Where
- 3 sites in Argentina, Chile
- Volunteers
- 217 people
- Sponsor
- MedImmune LLC
Respiratory Syncytial Virus Infections
A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance
The purpose of this study is to assess pregnancy outcomes, and maternal, as well as neonatal events of interest in healthy pregnant women and their new-borns.
- Trial name
- PEPNI (NCT03614676)
- Testing
- Blood sample collection, Cord blood sample collection, Maternal Diary Card
- Where
- 40 sites in Argentina, Bangladesh and 8 more
- Volunteers
- 4,493 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, COVID-19
Combined Molecular Testing for Influenza, SARS-CoV-2, and RSV RNA From Different Upper Airway Specimens.
This is a comparative prospective diagnostic accuracy study reported according to the STARD guidelines. Citizens at an outpatient COVID19 test facility at Testcenter Danmark Valby will be invited to participate in the study on a…
- Conditions
- Influenza, COVID-19, RSV Infection
- Trial name
- NCT05765838
- Testing
- (NPS right - Nasal swab left - OPS), (NPS left - Nasal swab right - OPS), (Nasal swab right - NPS left - OPS)
- Where
- Denmark
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Asthma in Children
The Long-term Effect of RSV Infection
Respiratory Syncytial Virus (RSV) is a leading cause of childhood illness and hospitalization across the world. In addition to acute mortality and morbidity, RSV infection is associated with developing recurrent wheeze in…
- Trial name
- NCT03876249
- Testing
- exposure to RSV
- Volunteers
- 2,000 people
- Sponsor
- Child Health Research Foundation, Bangladesh
Severe Bronchiolitis
Prone Position Effects on Work of Breathing and Intrinsic PEEP in Children With Severe Acute Viral Bronchiolitis
Acute viral bronchiolitis is the first cause of respiratory distress in infant. Airway inflammation increases the respiratory system resistances and dynamic hyperinflation. This leads to an increase in the work of breathing.
- Trial name
- BRONCHIO-DV (NCT02602678)
- Testing
- Supine then Prone position, Prone then supine position
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Hospices Civils de Lyon
RSV Infection
RSV Study in Adults 60 to 75 Years of Age
The purpose of this study is to infect healthy volunteers aged 60-75 years old with Respiratory Syncytial Virus (RSV) to confirm how safe and well tolerated the use of an experimental RSV virus is in a population that has not…
- Trial name
- NCT03919591
- Testing
- Challenge virus RSV-A Memphis 37b
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hvivo
Respiratory Syncytial Virus (RSV), Influenza A(H5N1)
Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5 (H5) antigen in healthy participants aged 18 to…
- Trial name
- NCT07516418
- Testing
- H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3
- Where
- 6 sites in Australia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi
RSV Infection
RSV Vaccination in Immunocompromised Patients.
Respiratory syncytial Virus (RSV) causes respiratory infections worldwide and typically presents with a seasonal pattern peaking in autumn/winter in temperate climate zones.
- Trial name
- NCT06597916
- Testing
- Arexvy powder and suspension for injection
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
RSV Infection
Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects
A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
- Trial name
- NCT04871724
- Testing
- EDP-938, Fluconazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Respiratory Syncytial Virus (RSV)
Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection
The primary objective of this study is to evaluate the effect of presatovir on nasal respiratory syncytial virus (RSV) viral load in RSV-positive lung transplant (LT) recipients with acute respiratory symptoms.
- Trial name
- NCT02534350
- Testing
- Presatovir
- Where
- 28 sites in United States, Australia and 6 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
Respiratory Syncytial Virus
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
The purpose of this study is to evaluate the efficacy of rilematovir compared to placebo with respect to the time to resolution of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) symptoms.
- Trial name
- PRIMROSE (NCT04978337)
- Testing
- Rilematovir
- Where
- 86 sites in United States, Argentina and 12 more
- Volunteers
- 5 people
- Sponsor
- Janssen Research & Development, LLC
Respiratory Synctial Virus Infections
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
Respiratory syncytial virus (RSV) is the most common respiratory infectious pathogen recognized worldwide that poses serious health risks to infants, and an important cause of hospitalization for severe respiratory infections in…
- Trial name
- NCT06775405
- Testing
- AK0529
- Where
- 18 sites in China
- Volunteers
- 180 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Lower Respiratory Tract Illness
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: At a dose of…
- Trial name
- RENOIR (NCT05035212)
- Testing
- RSVpreF
- Where
- 263 sites in United States, Argentina and 5 more
- Volunteers
- 38,861 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus Infections
Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany
The SYNAGIS Registry was carried out in order to gather comprehensive real-world data on the use of palivizumab in children at high risk for serious respiratory syncytial virus (RSV) disease.
- Trial name
- NCT01155193
- Volunteers
- 30,804 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Vaccination, Respiratory Syncytial Virus (RSV)
Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients
The purpose of this study is to compare the immunogenicity and safety of respiratory syncytial virus (RSV) vaccination between lung transplant recipients and immunocompetent adults and to provide evidence to guide RSV vaccination…
- Conditions
- Vaccination, Respiratory Syncytial Virus (RSV), Lung Transplant Recipient
- Trial name
- NCT07895394
- Testing
- RSVPreF3 vaccination
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Seoul National University Hospital
Bronchiolitis, Viral
Chest Physiotherapy in Infants Between 0 and 12 Months Old With Acute Bronchiolitis SRV(+)
The purpose of this research is to determine the effect of prolonged slow expiration techniques, provoked coughing and standard therapy compared to chest wall manual vibration and standard therapy in infants between 0 and 12…
- Trial name
- NCT02853838
- Testing
- Prolonged slow expiration+provoked coughing, Manual chest wall vibration, Standard Therapy
- Where
- Chile
- Volunteers
- 204 people
- Sponsor
- Universidad del Desarrollo
SARS CoV 2 Infection, RSV Infections
Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections
Respiratory viral infections caused by influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 remain major causes of morbidity, hospitalization, and mortality among older adults worldwide.
- Conditions
- SARS CoV 2 Infection, RSV Infections, Influenza Infection
- Trial name
- AIRE-INT (NCT07643688)
- Volunteers
- 150 people
- Sponsor
- Fabiana Sherine Ganem dos Santos
Respiratory Syncytial Virus Infections
Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants
The purpose of this study was to evaluate the safety and immune response to a single intramuscular (IM) dose of GSK Biologicals' investigational RSV maternal vaccine (RSVPreF3) in healthy pregnant women 18-40 years of age and in…
- Trial name
- NCT04126213
- Testing
- RSV MAT 60 µg, RSV MAT 120 µg
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline